Androgen deprivation therapy for prostate cancer and dementia risk: a systematic review and meta-analysis
- PMID: 28349979
- DOI: 10.1038/pcan.2017.10
Androgen deprivation therapy for prostate cancer and dementia risk: a systematic review and meta-analysis
Abstract
Background: Androgen deprivation therapy (ADT) to treat prostate cancer may be associated with an increased risk of dementia, but existing studies have shown conflicting results. Here we synthesize the literature on the association of ADT for the treatment of prostate cancer with dementia risk.
Methods: We conducted a systematic review of articles reporting the outcome of dementia among individuals with prostate cancer in those exposed to ADT versus a lesser-exposed comparison group (for example, ADT versus no-ADT; continuous versus intermittent ADT) using PubMed (1966-present), Web of Science (1945-present), Embase (1966-present) and PsycINFO (1806-present). The search was undertaken on 4 December 2016 by two authors. We meta-analyzed studies reporting an effect estimate and controlling for confounding. Random- or fixed-effects meta-analytic models were used in the presence or absence of heterogeneity per the I2 statistic, respectively. Small study effects were evaluated using Egger and Begg's tests.
Results: Nine studies were included in the systematic review. Seven studies reported an adjusted effect estimate for dementia risk. A random-effects meta-analysis of studies reporting any dementia outcome, which included 50 541 individuals, showed an increased risk of dementia among ADT users (hazard ratio (HR), 1.47; 95% confidence interval (CI), 1.08-2.00; P=0.02). We separately meta-analyzed studies reporting all-cause dementia (HR, 1.46; 95% CI, 1.05-2.02; P<0.001) and Alzheimer's disease (HR, 1.25; 95% CI, 0.99-1.57; P=0.06). There was no evidence of bias from small study effects (Egger, P=0.19; Begg, P=1.00).
Conclusion: The currently available combined evidence suggests that ADT in the treatment of prostate cancer may be associated with an increased dementia risk. The potential for neurocognitive deficits secondary to ADT should be discussed with patients and evaluated prospectively.
Similar articles
-
Association of androgen deprivation therapy and depression in the treatment of prostate cancer: A systematic review and meta-analysis.Urol Oncol. 2017 Nov;35(11):664.e1-664.e9. doi: 10.1016/j.urolonc.2017.07.016. Epub 2017 Aug 10. Urol Oncol. 2017. PMID: 28803700 Review.
-
The Risk of New Onset Dementia and/or Alzheimer Disease among Patients with Prostate Cancer Treated with Androgen Deprivation Therapy: A Systematic Review and Meta-Analysis.J Urol. 2021 Jan;205(1):60-67. doi: 10.1097/JU.0000000000001341. Epub 2020 Aug 28. J Urol. 2021. PMID: 32856962
-
Quantifying observational evidence for risk of dementia following androgen deprivation therapy for prostate cancer: an updated systematic review and meta-analysis.Prostate Cancer Prostatic Dis. 2021 Mar;24(1):15-23. doi: 10.1038/s41391-020-00267-3. Epub 2020 Aug 19. Prostate Cancer Prostatic Dis. 2021. PMID: 32814845
-
No increased risk of dementia in patients receiving androgen deprivation therapy for prostate cancer: a 5-year follow-up study.Asian J Androl. 2017 Jul-Aug;19(4):414-417. doi: 10.4103/1008-682X.179528. Asian J Androl. 2017. PMID: 27232853 Free PMC article.
-
Addition of Docetaxel to Androgen Deprivation Therapy for Patients with Hormone-sensitive Metastatic Prostate Cancer: A Systematic Review and Meta-analysis.Eur Urol. 2016 Apr;69(4):563-573. doi: 10.1016/j.eururo.2015.09.013. Epub 2015 Sep 28. Eur Urol. 2016. PMID: 26422676 Review.
Cited by
-
Psychosocial Factors Associated with Cognitive Function in Prostate Cancer Survivors on Hormonal Treatments: A Systematic Review.Neuropsychol Rev. 2024 Apr 20. doi: 10.1007/s11065-024-09639-1. Online ahead of print. Neuropsychol Rev. 2024. PMID: 38642173 Review.
-
Ligand-gated ion channels as potential biomarkers for ADT-mediated cognitive decline in prostate cancer patients.Mol Carcinog. 2024 Jun;63(6):1051-1063. doi: 10.1002/mc.23708. Epub 2024 Mar 14. Mol Carcinog. 2024. PMID: 38482990
-
Androgen Deprivation Therapy for Prostate Cancer: Focus on Cognitive Function and Mood.Medicina (Kaunas). 2023 Dec 30;60(1):77. doi: 10.3390/medicina60010077. Medicina (Kaunas). 2023. PMID: 38256338 Free PMC article. Review.
-
The Construction and Validation of a Novel Ferroptosis-Related Gene Signature in Parkinson's Disease.Int J Mol Sci. 2023 Dec 6;24(24):17203. doi: 10.3390/ijms242417203. Int J Mol Sci. 2023. PMID: 38139032 Free PMC article.
-
Neurocognitive impairment in females with breast cancer treated with endocrine therapy and CDK4/6 inhibitors: a pharmacovigilance study using the World Health Organization's database.Front Pharmacol. 2023 Oct 20;14:1278682. doi: 10.3389/fphar.2023.1278682. eCollection 2023. Front Pharmacol. 2023. PMID: 37927591 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical